Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $8.8300 (3.21%) ($8.8300 - $8.8300) on Fri. Dec. 11, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.8% (three month average) | RSI | 41 | Latest Price | $8.8300(3.21%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -3.4% a day on average for past five trading days. | Weekly Trend | AUTL declines -2.5% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) ARKG(13%) LIT(13%) SKYY(13%) XBI(13%) BLOK(12%) | Factors Impacting AUTL price | AUTL will decline at least -2.4% in a week (0% probabilities). TBT(-8%) USO(-7%) UNG(-7%) VIXM(-6%) SHY(-2%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.4% (StdDev 4.8%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-4.91(-155.61%) | Resistance Level | $10.31 | 5 Day Moving Average | $9.81(-9.99%) | 10 Day Moving Average | $10.03(-11.96%) | 20 Day Moving Average | $10.31(-14.35%) | To recent high | -38.2% | To recent low | 3.2% | Market Cap | $461m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |